Showing results (241-250 of 105,852) with videos related to
Sort By:
Pageof 10,586
Phytotherapy Research : PTR|January 31, 2003
Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig modelJamie C Laurenz, Chad C Collier, Joseph O KutiJournal of Clinical Microbiology|July 26, 2019
Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone ConcentrationsIris H Chen, David P Nicolau, Joseph L KutiJournal of Critical Care|March 25, 2008
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysisEffie L Kuti, Aarti A Patel, Craig I ColemanSurgical Infections|January 26, 2006
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA ProgramChristine T Ong, Joseph L Kuti, David P Nicolau, et al.Connecticut Medicine|February 17, 2006
Polymyxins: older antibiotics for a new threatSu Young Lee, Joseph L Kuti, David P NicolauSurgical Infections|April 18, 2007
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profilingKathryn J Eagye, Joseph L Kuti, David P NicolauDiagnostic Microbiology and Infectious Disease|March 14, 2007
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentC Andrew DeRyke, Joseph L Kuti, David P NicolauCurrent Medical Research and Opinion|October 7, 2020
Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and bothChi Nguyen, Rakesh Luthra, Effie Kuti, et al.Current Opinion in Infectious Diseases|October 3, 2020
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organismsAbigail K Kois, David P Nicolau, Joseph L KutiAntimicrobial Agents and Chemotherapy|November 3, 2020
Imipenem/Cilastatin/Relebactam Alone and in Combination against <i>Pseudomonas aeruginosa</i> in the <i>In Vitro</i> Pharmacodynamic ModelIris H Chen, David P Nicolau, Joseph L KutiPageof 10,586